Salubris(002294) 同花顺财报·2025-03-28 13:01Financial Performance - The company reported a basic earnings per share of 0.5400 yuan for 2024, an increase of 3.85% compared to 0.5200 yuan in 2023 [1] - The net profit for 2024 was 6.02 billion yuan, reflecting a 3.79% increase from 5.8 billion yuan in 2023 [1] - Operating revenue reached 40.12 billion yuan, marking a 19.23% increase from 33.65 billion yuan in the previous year [1] - The return on equity (ROE) slightly decreased to 7.27% from 7.35% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 76,799.89 million shares, accounting for 68.91% of the circulating shares, with a decrease of 1,983.94 million shares compared to the previous period [1] - The largest shareholder, Xinlitai Pharmaceutical Co., Ltd., holds 63,527.94 million shares, representing 57.00% of the total share capital, with no change [2] - New entrants among the top shareholders include the Industrial and Commercial Bank of China with 1,623.31 million shares, representing 1.46% of the total [2] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share (including tax) [2]